These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27057638)

  • 41. Neuroendocrine tumors: treatment updates.
    Khagi S; Saif MW
    JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
    Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
    Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging use of everolimus in the treatment of neuroendocrine tumors.
    Gajate P; Martínez-Sáez O; Alonso-Gordoa T; Grande E
    Cancer Manag Res; 2017; 9():215-224. PubMed ID: 28684922
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.
    Gallo M; Malandrino P; Fanciulli G; Rota F; Faggiano A; Colao A;
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1209-1224. PubMed ID: 28405826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
    Wolin EM
    Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms.
    Jungels C; Deleporte A
    Curr Opin Oncol; 2021 Jul; 33(4):378-385. PubMed ID: 33973550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS; Beenhouwer D; Strosberg JR; Neary MP; Cherepanov D
    World J Gastroenterol; 2015 Feb; 21(6):1945-55. PubMed ID: 25684964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of everolimus on the expression of Ki-67 and caspase-3 in patients with neuroendocrine tumors.
    Zhang HY; Cheng XB; Li Y; Jin LD; Yin HP
    Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28363001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
    Capdevila J; Sevilla I; Alonso V; Antón Aparicio L; Jiménez Fonseca P; Grande E; Reina JJ; Manzano JL; Alonso Lájara JD; Barriuso J; Castellano D; Medina J; López C; Segura Á; Carrera S; Crespo G; Fuster J; Munarriz J; García Alfonso P
    BMC Cancer; 2015 Jul; 15():495. PubMed ID: 26138480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
    Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F
    Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.
    Claringbold PG; Turner JH
    Cancer Biother Radiopharm; 2015 Aug; 30(6):261-9. PubMed ID: 26181854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
    Eriksson B
    Curr Opin Oncol; 2010 Jul; 22(4):381-6. PubMed ID: 20473165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Everolimus in the management of metastatic neuroendocrine tumours.
    Chan DL; Segelov E; Singh S
    Therap Adv Gastroenterol; 2017 Jan; 10(1):132-141. PubMed ID: 28286565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.